Tag: immunization

Home / immunization
Post

Second dose of COVID-19 Vaccination

NACI has provided updated recommendations on COVID-19 vaccine schedules. For those who have received a first dose of an AstraZeneca vaccine, an mRNA vaccine is preferred for the second dose due to emerging evidence suggesting better immune response, and, to mitigate the risk of VITT(Vaccine-Induced Thrombotic Thrombocytopenia) from viral vector vaccines. HMC

Post

Peel residents aged 50 and over in select hot spot postal codes now eligible to receive COVID-19 vaccine

Peel residents 50 years of age and older, living in hotspot postal codes, are now eligible to book vaccine appointments at Peel Public Health and hospital clinics.  In Peel, the list of hotspot postal codes includes: L4T, L4W, L4X, L4Z, L5A, L5B, L5R, L5C, L5K, L5L, L5M, L5N, L5V, L5W, L6P, L6R, L6S, L6T, L7C,...

Post

Janssen (Johnson and Johnson) COVID-19 Vaccine

On March 5, 2021, Health Canada authorized the use of the Janssen (Johnson and Johnson) vaccine. This vaccine is an adenovirus vector vaccine administered through a single dose. More information about the Janssen vaccine including how it works, how it’s given and possible side effects is available at https://www.canada.ca/en/health- canada/services/drugs-health-products/covid19- industry/drugs-vaccines- treatments/vaccines/janssen.html HMC

Post

Astra Zeneca/COVISHEILD COVID-19 Vaccine

On February 26, 2021, Health Canada authorized the use of the Astra Zeneca/COVISHELD vaccine. This vaccine is an adenovirus vector vaccine and is administered through two doses. More information about the AstraZeneca vaccine including how it works, how it’s given and possible side effects is available at https://www.canada.ca/en/health- canada/services/drugs-health-products/covid19- industry/drugs-vaccines- treatments/vaccines/astrazeneca.html HMC

Post

3 Approved COVID-19 Vaccines Efficacy

Interim results of two large randomized, placebo-controlled trials (RCTs) demonstrate ~95% relative efficacy in preventing COVID-19 (Pfizer, Moderna). The AstraZeneca/Oxford vaccine has ~70% relative efficacy. Absolute benefits will vary with baseline risk and time but if annual risk of developing COVID-19 is 20%, then vaccine would decrease risk to 1% (6% with AstraZeneca/Oxford). These vaccines...